SPRED3 Inhibitors
Chemical inhibitors of SPRED3 operate by targeting different components of the signaling pathways in which the protein is involved. PD98059 and U0126 are both selective inhibitors of MEK, a kinase that functions upstream of ERK in the Ras/Raf/ERK pathway, which is negatively regulated by SPRED3. By preventing the phosphorylation and activation of ERK, these inhibitors could lead to a reduction in the regulatory effects of SPRED3 on the pathway. LY294002 and Wortmannin are inhibitors of PI3K, a key player in the Akt pathway that is known to interact with the Ras/Raf/ERK pathway. The inhibition of PI3K by these chemicals could therefore diminish the downstream signal that contributes to the regulation by SPRED3. Rapamycin, by inhibiting mTOR, a downstream effector of PI3K/Akt signaling, can also indirectly suppress the activity within the ERK pathway, thereby inhibiting the function of SPRED3.
Moreover, SB203580 and BIRB 796 are inhibitors of p38 MAP kinase, another MAP kinase pathway that can affect the dynamics of the ERK pathway. Through their action, they could lead to changes in the signaling cascade, resulting in the functional inhibition of SPRED3. SP600125, which inhibits JNK, can also decrease signaling through the ERK pathway, thereby inhibiting SPRED3. SL327 and PD0325901, both selective inhibitors of MEK, serve to prevent the activation of ERK, further inhibiting the regulatory effects SPRED3 has on this pathway. Lastly, Sorafenib and Sunitinib target multiple tyrosine protein kinases, such as VEGFR and PDGFR, and serine/threonine kinases like Raf-1 and BRAF. By suppressing the activity of these kinases, these inhibitors can downregulate the Ras/Raf/ERK pathway's activity, leading to the functional inhibition of the regulatory role SPRED3 plays within this pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of extracellular signal-regulated kinases (ERKs). SPRED3 negatively regulates the Ras/Raf/ERK pathway. By inhibiting MEK and therefore ERK phosphorylation, PD98059 can indirectly inhibit SPRED3's interaction with the pathway, leading to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor which prevents the activation of ERK1/2. Since SPRED3 functions through the Ras/Raf/ERK signaling pathway, inhibition of MEK by U0126 would result in the suppression of ERK activation, thereby functionally inhibiting SPRED3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in the Akt pathway. By inhibiting PI3K, LY294002 could diminish Akt pathway signaling, which has been shown to interact with the Ras/Raf/ERK pathway that SPRED3 is part of, resulting in the functional inhibition of SPRED3. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific inhibitor of PI3K. By decreasing PI3K activity, it downregulates the PI3K/Akt pathway, which is known to crosstalk with the Ras/Raf/ERK pathway that involves SPRED3. The inhibition of this pathway by Wortmannin can thus lead to the functional inhibition of SPRED3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits the mammalian target of rapamycin (mTOR), a downstream effector of PI3K/Akt signaling. Since SPRED3 is involved in the Ras/Raf/ERK pathway, the inhibition of mTOR by Rapamycin can indirectly inhibit SPRED3 by reducing signaling through the ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is another MAP kinase pathway that can have regulatory effects on the ERK pathway, where SPRED3 is involved. Inhibiting p38 MAP kinase with SB203580 could lead to changes in the ERK pathway dynamics, thus functionally inhibiting SPRED3. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which plays a role in various cellular processes that can intersect with the Ras/Raf/ERK signaling pathway. By inhibiting JNK, SP600125 may lead to a decrease in ERK pathway signaling, resulting in the functional inhibition of SPRED3. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is a selective inhibitor of MEK, which is upstream of the ERK kinase that SPRED3 regulates. By inhibiting MEK activity, SL327 would prevent ERK activation, leading to the functional inhibition of SPRED3 by reducing its regulatory effects on the ERK pathway. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 796 is a potent inhibitor of p38 MAP kinase. By inhibiting p38 MAPK, BIRB 796 could indirectly affect the Ras/Raf/ERK pathway, leading to the functional inhibition of SPRED3 due to a reduction in ERK pathway signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several tyrosine protein kinases, such as VEGFR and PDGFR, and the serine/threonine kinases Raf-1 and BRAF. These kinases are part of the Ras/Raf/ERK pathway that SPRED3 is known to regulate. Sorafenib's action can result in the functional inhibition of SPRED3 by suppressing the pathway's activity. | ||||||